Posted by Michael Wonder on 29 Jun 2020
ICER to assess treatments for anaemia in chronic kidney disease
26 June 2020 - Report will be subject of CTAF meeting in Feburary 2021; Open Input now being accepted until 15 July 2020.
The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of roxadustat (FibroGen) for treatment of anaemia in chronic kidney disease. Roxadustat is currently undergoing FDA review, with an anticipated decision expected at the end of this year.
The assessment will be publicly discussed during a meeting of the California Technology Assessment Forum in February 2021, where the independent evidence review panel will deliberate and vote on evidence presented in ICER’s report.
